Neuroleptic malignant syndrome can complicate antipsychotic treatment in pregnant women, highlighting the need to balance the risks of untreated psychosis with adverse drug effects.
Answers are grounded in this paper and cite their sources.
NMS risk in pregnancy warrants vigilance with antipsychotics; case reports leave optimal agent selection open.
BACKGROUND: Neuroleptic malignant syndrome (NMS) is characterized by a tetrad of mental status changes, extrapyramidal symptoms, hyperpyrexia, and autonomic instability and can develop after the use of antipsychotics. CASE: A young, multiparous woman presented at 26 weeks of gestation with acute psychosis and was treated with haloperidol until she developed rigidity of her extremities and then was switched to risperidone. She subsequently developed mental status changes, rigidity, hyperthermia, and autonomic instability, leading to a diagnosis of NMS. Risperidone was discontinued and, owing to ongoing psychosis, olanzapine was initiated. Subsequently, her symptoms resolved. CONCLUSION: Neuroleptic malignant syndrome may complicate the treatment of pregnant women using antipsychotics. Clinicians should take into account the risks of untreated psychosis when discontinuing the offending agent and consider initiating alternative pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Ghaffari et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: